Credit Suisse Group AG restated their buy rating on shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in a research note released on Wednesday morning. The brokerage currently has a $101.00 target price on the biopharmaceutical company’s stock.

RARE has been the topic of several other reports. Morgan Stanley reiterated a hold rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, June 8th. Leerink Swann restated a buy rating and set a $85.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, July 15th. Jefferies Group restated a buy rating on shares of Ultragenyx Pharmaceutical in a research note on Sunday, July 17th. Piper Jaffray Cos. assumed coverage on shares of Ultragenyx Pharmaceutical in a research note on Thursday, July 7th. They set an overweight rating and a $70.00 price objective on the stock. Finally, JMP Securities restated a buy rating and set a $84.00 price objective (up from $80.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, June 8th. Three equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $97.32.

Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at 76.58 on Wednesday. Ultragenyx Pharmaceutical has a 52-week low of $46.52 and a 52-week high of $117.12. The firm’s market cap is $3.02 billion. The company has a 50-day moving average of $67.24 and a 200 day moving average of $62.97.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.44) by $0.02. During the same quarter in the previous year, the business posted ($0.83) EPS. On average, equities research analysts anticipate that Ultragenyx Pharmaceutical will post ($5.93) EPS for the current year.

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, July 15th. The shares were sold at an average price of $50.85, for a total value of $1,017,000.00. Following the completion of the transaction, the chief executive officer now directly owns 513,597 shares in the company, valued at approximately $26,116,407.45. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Sunil Agarwal sold 649 shares of the company’s stock in a transaction that occurred on Thursday, July 21st. The shares were sold at an average price of $52.68, for a total transaction of $34,189.32. The disclosure for this sale can be found here. 10.10% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP boosted its position in shares of Ultragenyx Pharmaceutical by 79.9% in the first quarter. Wellington Management Group LLP now owns 4,132,430 shares of the biopharmaceutical company’s stock valued at $261,625,000 after buying an additional 1,835,196 shares during the period. Norges Bank acquired a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter valued at about $34,393,000. State Street Corp boosted its position in shares of Ultragenyx Pharmaceutical by 30.6% in the first quarter. State Street Corp now owns 1,284,324 shares of the biopharmaceutical company’s stock valued at $81,315,000 after buying an additional 300,901 shares during the period. Pictet Asset Management Ltd. boosted its position in shares of Ultragenyx Pharmaceutical by 2,459.6% in the second quarter. Pictet Asset Management Ltd. now owns 194,527 shares of the biopharmaceutical company’s stock valued at $14,220,000 after buying an additional 186,927 shares during the period. Finally, Lord Abbett & CO. LLC boosted its position in shares of Ultragenyx Pharmaceutical by 116.3% in the second quarter. Lord Abbett & CO. LLC now owns 337,153 shares of the biopharmaceutical company’s stock valued at $16,490,000 after buying an additional 181,270 shares during the period. Hedge funds and other institutional investors own 93.06% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

5 Day Chart for NASDAQ:RARE

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.